Washington, D.C. 20549







CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 24, 2019





(Exact name of registrant as specified in its charter)




(State or Other Jurisdiction of Incorporation)


(Commission File Number)

(I.R.S. Employer Identification No.)


Block 10-1

Blanchardstown Corporate Park, Ballycoolin

Dublin 15, Ireland

(Address of Principal Executive Offices)

Not Applicable

(Zip Code)


Registrant’s telephone number, including area code: +353 1 485 1200



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Ticker symbol(s)


Name of each exchange on which registered

American Depositary Shares*   AVDL   NASDAQ Stock Market LLC
Ordinary Shares**       (NASDAQ Global Market)


* American Depositary Shares may be evidenced by American Depository Receipts. Each American Depositary Share represents one (1) Ordinary Share.


** Nominal value $0.01 per share. Not for trading, but only in connection with the listing of American Depositary Shares.






Item 7.01 Regulation FD Disclosure.


On September 24, 2019, Avadel Pharmaceuticals plc (the “Company”) intends to make a presentation at the Ladenburg Thalmann 2019 Healthcare Conference in New York, New York (the “Conference”). A copy of the Company’s complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s presentation will be webcast live and can be accessed by visiting the Investor section of the Company’s website at http://www.avadel.com. A replay of the presentation, together with the complete slide presentation, will also be available and archived for 90 days on the website following the event.


The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


99.1 Slide Presentation of Avadel Pharmaceuticals plc as of September 24, 2019







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By:   /s/ Phillandas T. Thompson
    Phillandas T. Thompson
    Senior Vice President, General Counsel and Corporate Secretary


Date: September 24, 2019




Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Avadel Pharmaceuticals Charts.
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Avadel Pharmaceuticals Charts.